Q2 2021 13F Holders as of 6/30/2021
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
131M
-
Number of holders
-
160
-
Total 13F shares, excl. options
-
49.1M
-
Shares change
-
-3.23M
-
Total reported value, excl. options
-
$636M
-
Value change
-
-$41.9M
-
Put/Call ratio
-
1.37
-
Number of buys
-
83
-
Number of sells
-
-71
-
Price
-
$12.96
Significant Holders of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) as of Q2 2021
218 filings reported holding AUPH - Aurinia Pharmaceuticals Inc. - Common Shares, no par value as of Q2 2021.
Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) has 160 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49.1M shares
of 131M outstanding shares and own 37.54% of the company stock.
Largest 10 shareholders include FMR LLC (8.52M shares), ORBIMED ADVISORS LLC (6.07M shares), NEA Management Company, LLC (5.17M shares), MORGAN STANLEY (3.62M shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (2.42M shares), PICTET ASSET MANAGEMENT LTD (2.17M shares), KINGDON CAPITAL MANAGEMENT, L.L.C. (1.58M shares), BAKER BROS. ADVISORS LP (1.12M shares), Artal Group S.A. (1M shares), and WELLS FARGO & COMPANY/MN (788K shares).
This table shows the top 160 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.